Résztvevőt keres1/2. fázis
Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)
A legfontosabb adatok
- Ki végzi
- Shanghai Mianyi Biopharmaceutical Co., Ltd.
- Hol
- Kína4 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1/2. fázis
- Résztvevők
- 60 fő, tervezett
- Kezdés
- 2026. aug. 26.
- Várható befejezés
- 2029. dec. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- BBM-C101
- A regiszteradat frissítve
- 2026. november 16.
Ki vehet részt
- Életkor
- 18 év – 55 év
- Nem
- Csak nők
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 25 feltétel megnézéseKevesebb
Ki vehet részt
- Histologically confirmed HPV16 and/or HPV18 associated HSIL
- Colposcopy findings at screening at each study center must meet all of the following conditions: The colposcopy examination should be satisfactory and The ECC result must be negative
- Women of childbearing potential must agree to use highly effective contraception together with their partner throughout the study and for at least 1 year after the first dose ; f and a serum pregnancy test within 7 days prior to enrollment must be negative
- Willing to voluntarily participate in the study and provide written informed consent
- In the opinion of the Investigator, the participant is expected to demonstrate good compliance and be able to complete all scheduled visits and follow-up assessments in accordance with the study protocol ; -
Ki nem vehet részt
- Participants who have received any treatment for HPV positivity or cervical HSIL prior to study drug
- History of previous therapeutic HPV vaccination ( except for the licensed prophylactic HPV vaccines )
- Participants who have used any local or systemic immunosuppressive agents prior to the first administration of BBM-C101 injection
- Received any licensed vaccines within 2 weeks prior to study drug administration
- Having participated in other clinical trials before signing the informed consent form, including studies involving investigational drugs or devices
- Participants who have received any gene therapy treatment prior to screening, or plans to receive any other gene therapy treatment during the study period
- Participants with unstable cardiovascular or cerebrovascular diseases, defined as clinical cardiovascular event (such as unstable angina, myocardial infarction, stroke, etc.) occurring within 3 months prior to screening; participants with severe uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg)
- Active drug or alcohol use or dependence that, in the opinion of the Investigator, would interfere with adherence to study requirements
- Major surgery or significant trauma within 4 weeks prior to the first dose
- Participants with acute cervical inflammation or acute exacerbation of chronic cervical disease
- Positive results were obtained in the tests for hepatitis C virus antibody, human immunodeficiency virus (HIV)
- Participants with a history or diagnosis of autoimmune diseases, including but not limited to Crohn's disease, ulcerative colitis, systemic lupus erythematosus, sarcoidosis, Wegener's granulomatosis, Graves' disease, rheumatoid arthritis, hypophysitis , uveitis, autoimmune hepatitis, systemic sclerosis, autoimmune vasculitis, autoimmune neuropathy (Guillain-Barré syndrome), etc
- Participants with active infections requiring systemic anti-infective therapy
- Participants with a known history of malignant tumors in any organ/system (regardless of evidence of local recurrence or metastasis)
- Participants with a history of severe allergic diseases ( e.g., allergy-related shock, dyspnea, angioedema) )
- Any other conditions judged by the Investigator that may affect a participant's safety or compliance ; -
- Participants with clinically significant abnormal values in laboratory tests during screening, as determined by the Investigator to increase risk to the participant's participation in the clinical trial . This includes, but is not limited to, any of the following:; White blood cell count < 3.0 × 10⁹/L; Hemoglobin < 90 g/L; Platelet < 100 × 10⁹/L; Aspartate aminotransferase or alanine aminotransferase > 2 × upper limit of normal (ULN); Total bilirubin > 1.5 × ULN; Creatinine > 1.5 × ULN
- During screening, cytological or histopathological shows any of the following results: adenocarcinoma in situ (AIS), atypical glandular cells-favor neoplasia (AGC-FN), or invasive carcinoma
- Participants who are unable or unwilling to undergo colposcopy, or have contraindications to colposcopy
- Pregnant or breastfeeding (lactating)
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 55 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Kína.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this study is to learn about the safety, tolerability, immunogenicity and preliminary efficacy of BBM-C101 injection in patients with High-Grade Squamous Intraepithelial Lesion of the cervix.
A teljes eredeti leírásKevesebb
This study include two phases: Phase I and Phase IIa .
A vizsgálat csoportja
- Arm of BBM-C101A vizsgált kezelés
Kezelés: BBM-C101
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase I/ IIa, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesions.
- Kérdések a feltételekről
- Forrás: NCT07668960: ki vehet részt
- A regiszteradat frissítve
- 2026. november 16.